ATP23 Antibody

What is ATP23 and why is it significant in research?

ATP23 is a metalloprotease and ATP synthase assembly factor homolog that plays crucial dual roles in cellular function. In yeast (Saccharomyces cerevisiae), it functions as both a processing peptidase for subunit 6 of mitochondrial ATPase and as a chaperone facilitating the assembly of the F₀ component of ATP synthase . In humans, ATP23 is particularly noteworthy as it is amplified in glioblastomas and interacts with the DNA binding subunit of DNA-dependent protein kinase (DNA-PK), which is involved in double-strand break repair (DSB) . The protein's conservation from yeast to humans underscores its evolutionary importance in cellular metabolism and energy production, making it a valuable target for both basic biological research and potential therapeutic applications in oncology .

Where is ATP23 localized in cells and how does this affect antibody selection?

ATP23 is primarily localized in the intermembrane space of mitochondria, with evidence showing it behaves as a soluble protein rather than an integral membrane protein . Subcellular fractionation experiments have confirmed its exclusive presence in mitochondrial fractions, similar to other mitochondrial proteins like Tom40 . This mitochondrial localization is critical for researchers when selecting appropriate antibodies and designing immunodetection protocols. When studying ATP23, researchers should consider using antibodies that maintain specificity under conditions needed for mitochondrial protein detection, including sample preparation methods that effectively extract and preserve mitochondrial proteins while reducing cytosolic contamination . Additionally, permeabilization techniques for immunocytochemistry should be optimized to ensure antibody access to mitochondrial compartments.

What are the known biological processes involving ATP23?

ATP23 participates in several critical biological processes based on current research:

• Mitochondrial ATP synthase assembly - ATP23 functions as a chaperone that promotes the association of mature Atp6 with Atp9 oligomers, facilitating the assembly of the F₀ component of ATP synthase

• Protein processing - ATP23 serves as a processing peptidase that mediates the maturation of mitochondrial-encoded F₀-subunit Atp6 after its insertion into the inner membrane

• Double-strand break repair - Human ATP23 interacts with the DNA binding subunit of DNA-dependent protein kinase involved in DSB repair, with higher expression increasing repair efficiency

• Mitochondrial protein folding - Evidence suggests ATP23 works in conjunction with the mitochondrial intermembrane space assembly (MIA) pathway, specifically interacting with Mia40 during its biogenesis

These diverse functions highlight ATP23's multifaceted role in cellular homeostasis and energy metabolism, making antibodies against this protein valuable tools for studying mitochondrial biology, DNA repair mechanisms, and cancer biology .

How does the dual function of ATP23 affect experimental design when using ATP23 antibodies?

The dual function of ATP23 as both a metalloprotease and a chaperone creates unique considerations for experimental design. Notably, studies have shown that proteolytically inactive ATP23 mutants can still assemble functional ATPase complexes despite accumulating subunit 6 precursors . This functional duality necessitates careful experimental planning when using ATP23 antibodies:

• Function-specific analysis requires distinguishing between ATP23's proteolytic and chaperone activities. Researchers should consider using site-directed mutagenesis to create proteolytically inactive variants (targeting the metalloprotease domain) while preserving chaperone function .

• When designing immunoprecipitation experiments, researchers must account for ATP23's different interaction partners depending on which function is being investigated. For chaperone function studies, protocols should preserve weaker, transient protein-protein interactions that characterize chaperone activities .

• Quantitative analyses should differentiate between ATP23's association with substrate processing (proteolytic function) versus substrate folding/assembly (chaperone function), potentially requiring multiple antibodies targeting different epitopes or conformational states of ATP23 .

This functional complexity means researchers must clearly define which aspect of ATP23 biology they're investigating and design antibody-based experimental approaches accordingly.

What considerations are important when studying ATP23 in the context of mitochondrial disease models?

When investigating ATP23 in mitochondrial disease models, several important factors must be considered:

• ATP23 deletion in yeast causes respiratory deficiency with severely depressed levels of cytochromes a, a₃, and b, alongside deficiency in subunit 6 but not subunit 4 or the α-subunit of F₁ . These differential effects on respiratory chain components require careful experimental design when translating to human disease models.

• The interaction between ATP23 and prohibitins (membrane proteins that form ring-like assemblies with proposed scaffolding functions) suggests complex regulatory networks affecting mitochondrial membrane organization . Researchers should consider co-immunoprecipitation experiments with ATP23 antibodies to capture these interactions in disease contexts.

• ATP23's involvement in both mitochondrial function and DNA repair indicates potential cross-talk between these cellular processes . Disease model studies should examine both pathways simultaneously rather than in isolation.

• When using ATP23 antibodies in disease models, researchers should validate antibody specificity across species and account for potential post-translational modifications that might affect epitope recognition in pathological states .

A comprehensive experimental approach should include multiple readouts of mitochondrial function (membrane potential, ATP production, respiratory capacity) alongside ATP23 detection to fully characterize its role in disease pathogenesis.

How does the redox state of ATP23 impact antibody recognition and experimental outcomes?

The redox state of ATP23 significantly impacts its structural conformation and function, which directly affects antibody recognition and experimental results. Research has demonstrated that ATP23 undergoes redox-dependent modifications that can be assessed using techniques like mPEG modification following TCA precipitation . This redox sensitivity creates several important considerations:

• Sample preparation methods must preserve the native redox state of ATP23. Researchers should consider including reducing or oxidizing agents in extraction buffers depending on the specific research question. For Western blotting applications, non-reducing conditions may be necessary to maintain certain conformational epitopes .

• ATP23's interaction with the mitochondrial protein Mia40 appears to be redox-dependent, suggesting ATP23 contains critical cysteine residues involved in disulfide bonding. Antibodies targeting regions containing these cysteines may show differential recognition depending on the oxidation state .

• Experimental data interpretation should account for potential redox-dependent changes in ATP23 abundance or migration patterns on gels. Controls using reducing agents (like TCEP) versus oxidizing agents (like copper phenanthroline) can help distinguish genuine antibody recognition from artifacts .

• For researchers investigating ATP23 function under different oxygen conditions, special attention should be paid to how hypoxia or hyperoxia might affect ATP23 structure and antibody recognition, as studies have examined ATP23 redox state both in the presence and absence of oxygen .

These considerations are particularly important for ensuring reliable and reproducible results when using ATP23 antibodies across different experimental conditions.

What are the optimal applications for different types of ATP23 antibodies?

Different ATP23 antibodies have specific optimal applications based on their characteristics and validation data:

When selecting an ATP23 antibody, researchers should consider:

• The nature of the sample (fixed tissue, cell lysate, purified protein)

• The experimental technique (WB, IHC, ELISA, IP)

• The species being studied

• Whether native or denatured protein detection is required

For optimal results in mitochondrial fractionation studies, antibodies validated for specific subcellular compartments should be prioritized, as ATP23's localization in the intermembrane space may require specialized extraction and detection protocols .

What are the recommended protocols for detecting ATP23 in mitochondrial fractions?

Detecting ATP23 in mitochondrial fractions requires specialized protocols to ensure accurate subcellular localization and optimal antibody performance:

Recommended Mitochondrial Fractionation Protocol:

• Isolate mitochondria using differential centrifugation techniques. For yeast studies, cell rupturing with glass beads in appropriate buffer has been effective .

• Verify mitochondrial purity using markers like Tom40 (outer membrane) and exclude cytosolic contamination using markers like Bmh1 .

• For submitochondrial localization:

  • Perform protease protection assays by treating intact mitochondria with proteases (e.g., proteinase K)

  • Conduct alkaline extraction (pH 11.5) to differentiate between membrane-integrated proteins and soluble/peripherally associated proteins

  • Compare ATP23 behavior with known markers (e.g., cytochrome b₂ for intermembrane space)

• For Western blot detection:

  • Use SDS-PAGE with 10-12% gels for optimal ATP23 resolution

  • Include reducing agents (DTT or β-mercaptoethanol) in sample buffer

  • Transfer proteins to PVDF membranes (preferred over nitrocellulose for mitochondrial proteins)

  • Block with 5% non-fat milk or BSA in TBS-T

  • Incubate with ATP23 antibody at manufacturer-recommended dilution (typically 1:1000 for most commercial antibodies)

  • Visualize using appropriate secondary antibodies and detection systems

For immunohistochemical detection in tissues, additional steps for mitochondrial preservation and membrane permeabilization may be necessary to ensure antibody access to the intermembrane space where ATP23 resides .

How can researchers validate ATP23 antibody specificity for their experimental system?

Validating ATP23 antibody specificity is crucial for accurate interpretation of experimental results. Here's a comprehensive approach to antibody validation:

• Genetic validation using knockout/knockdown models:

  • Compare antibody signal between wild-type and ATP23-deleted cells. Complete absence of signal in knockout samples provides strong validation of specificity .

  • For partial knockdown, correlation between reduced ATP23 mRNA levels and protein signal provides supporting evidence of specificity.

• Epitope mapping:

  • Use peptide dot blot assays with synthesized 20-amino acid peptides covering the ATP23 sequence (with 3-amino acid frame shifts between spots) to identify the exact binding region of the antibody .

  • Competition assays with purified recombinant ATP23 or specific peptides can confirm binding specificity.

• Cross-reactivity assessment:

  • Test antibody against recombinant ATP23 from different species if cross-species applications are intended.

  • Check for potential cross-reactivity with related metalloproteases by immunoblotting in samples expressing these proteins.

• Application-specific validation:

  • For Western blotting: Verify that the detected band matches the predicted molecular weight of ATP23 (accounting for potential post-translational modifications)

  • For immunoprecipitation: Confirm enrichment of ATP23 by mass spectrometry analysis of immunoprecipitated samples

  • For immunohistochemistry: Compare staining pattern with known mitochondrial distribution and include appropriate controls

• Specificity controls:

  • Pre-adsorption control: Pre-incubate antibody with excess antigen before application to eliminate specific binding

  • Secondary antibody-only control: Verify absence of non-specific binding by secondary antibody

These validation approaches should be adapted based on the specific experimental context and available resources.

How should researchers interpret inconsistent ATP23 antibody signals across different experimental conditions?

Inconsistent ATP23 antibody signals across experimental conditions can stem from several factors that should be systematically evaluated:

• Redox state variability: ATP23 contains cysteine residues that undergo redox-dependent modifications, potentially affecting antibody recognition. Researchers should standardize reducing/oxidizing conditions during sample preparation or deliberately examine both states using agents like TCEP (reducing) or copper phenanthroline (oxidizing) .

• Alternative isoforms: ATP23 has several transcript variants encoding different isoforms . Inconsistent signals may reflect differential expression of these isoforms across experimental conditions. Western blots might show multiple bands representing different isoforms, requiring isoform-specific primers for qPCR validation.

• Subcellular redistribution: ATP23 primarily localizes to mitochondria but may redistribute under stress conditions or in disease states. Fractionation controls comparing cytosolic versus mitochondrial fractions can help resolve this issue .

• Protein-protein interactions: ATP23 interacts with multiple partners (Atp6, Atp9, Mia40, prohibitins), and these interactions might mask antibody epitopes in certain conditions. Native versus denaturing conditions may yield different results .

• Post-translational modifications: Functional changes to ATP23 may involve modifications affecting antibody recognition. Phosphatase or deglycosylation treatments prior to immunoblotting can help determine if such modifications contribute to signal variability.

When analyzing inconsistent results, researchers should implement a systematic approach that includes multiple antibodies targeting different epitopes, alongside complementary techniques like mass spectrometry or fluorescently-tagged ATP23 to validate observations.

What are common pitfalls when using ATP23 antibodies in co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) with ATP23 antibodies presents several challenges that researchers should anticipate and address:

• Preservation of physiological interactions: ATP23 functions as a chaperone with potentially transient interactions. Standard Co-IP buffers might disrupt these interactions. Consider using gentle crosslinking agents (like DSP or formaldehyde) or milder detergents (digitonin instead of Triton X-100) to preserve weaker interactions .

• Antibody orientation effects: The binding of antibodies to ATP23 might sterically hinder interactions with specific partners. Testing both N-terminal and C-terminal targeting antibodies can help resolve this issue. Alternatively, epitope-tagged ATP23 constructs can be used for Co-IP through the tag .

• Mitochondrial membrane integrity: ATP23 resides in the mitochondrial intermembrane space, requiring careful mitochondrial isolation and solubilization for effective Co-IP. Inadequate solubilization may result in false negatives, while excessive detergent may disrupt genuine interactions .

• Redox-sensitive interactions: Some ATP23 interactions may be redox-dependent, particularly its interaction with Mia40 . Co-IP buffers should maintain the appropriate redox environment, potentially requiring the addition of reducing agents or oxidizing agents depending on the interaction being studied.

• Prohibitin complexes: ATP23 genetically interacts with prohibitins that form large ring-like assemblies . These macromolecular complexes may be difficult to preserve and isolate in standard Co-IP protocols. Consider using blue native PAGE instead of standard SDS-PAGE for analysis of these larger complexes.

For successful ATP23 Co-IP studies, researchers should optimize conditions based on the specific interaction partner being investigated, considering the cellular compartment and physiological context of the interaction.

How can researchers distinguish between ATP23's proteolytic versus chaperone functions in experimental data?

Distinguishing between ATP23's dual functions requires specialized experimental approaches:

• Mutational analysis approach:
  Create proteolytically inactive ATP23 mutants by targeting conserved metalloprotease motifs. These mutants will retain chaperone function while lacking proteolytic activity . Comparing wildtype versus mutant ATP23 in functional assays can separate the contributions of each function.

• Substrate processing analysis:
  Monitor Atp6 precursor processing using Western blotting with anti-Atp6 antibodies. Accumulation of precursor forms indicates defective proteolytic function, while assembled F₀ complex formation (despite precursor accumulation) indicates intact chaperone function .

• Genetic interaction analysis:
  ATP23 overexpression can suppress defects in ATP10 null mutants, suggesting functional overlap in chaperone activities . Use genetic complementation assays with various ATP23 constructs to dissect which domains contribute to which functions.

• In vitro activity assays:

  • For proteolytic function: Develop in vitro protease assays using recombinant ATP23 and synthetic peptide substrates

  • For chaperone function: Assess prevention of protein aggregation or assistance in protein folding using purified components

• Interaction partner profiling:
  Different ATP23 functions likely involve distinct sets of interaction partners. Use quantitative proteomics following immunoprecipitation with:

  • Wildtype ATP23 antibodies

  • Proteolytically inactive ATP23 antibodies

  • ATP23 antibodies under conditions that specifically preserve chaperone interactions

Comparative analysis of these datasets can identify proteins specifically associated with each functional state of ATP23 .

By combining these approaches, researchers can develop a comprehensive understanding of the relative contributions of ATP23's proteolytic versus chaperone functions in their experimental system.

How is ATP23 being studied in the context of DNA repair mechanisms and cancer biology?

ATP23's amplification in glioblastomas and interaction with DNA-dependent protein kinase (DNA-PK) positions it at an intriguing intersection between mitochondrial function and DNA repair, generating several research directions:

• Mechanistic studies of ATP23 in double-strand break repair:
  Research indicates ATP23 increases the efficiency of double-strand break (DSB) repair through its interaction with the DNA binding subunit of DNA-PK . Current investigations are using ATP23 antibodies to:

  • Track ATP23 recruitment to DSB sites using chromatin immunoprecipitation

  • Analyze ATP23-DNA-PK complex formation following induced DNA damage

  • Examine how ATP23 levels correlate with DNA repair efficiency in cancer cell lines

• Cancer therapeutic implications:
  Given ATP23's amplification in glioblastomas , researchers are investigating:

  • Correlation between ATP23 expression levels and cancer aggressiveness/treatment resistance

  • Whether ATP23 inhibition could sensitize cancer cells to DNA-damaging therapies

  • Development of ATP23 antibodies as potential diagnostic markers for tumors with DNA repair dysregulation

• Mitochondrial-nuclear signaling axis:
  ATP23's dual localization suggests it may participate in retrograde signaling between mitochondria and nucleus. Investigators are using fractionation approaches with ATP23 antibodies to:

  • Track ATP23 translocation between cellular compartments under stress conditions

  • Identify post-translational modifications that might regulate its subcellular distribution

  • Determine if ATP23's roles in mitochondria and DNA repair are functionally linked

These emerging research directions highlight the importance of ATP23 antibodies with verified specificity for both mitochondrial and nuclear fractions, as well as the need for antibodies that can distinguish between different functional states of the protein .

What technical advances are improving ATP23 detection and functional analysis?

Recent technical advances have enhanced our ability to study ATP23 biology:

• Proximity labeling techniques:
  BioID and APEX2 approaches, where ATP23 is fused to a promiscuous biotin ligase or peroxidase, allow identification of proximal proteins in living cells. This is particularly valuable for capturing transient interactions that occur during ATP23's chaperone function .

• Redox proteomics integration:
  Given ATP23's sensitivity to redox conditions , coupling of redox proteomics with ATP23 antibody-based enrichment allows tracking of ATP23's cysteine oxidation states under various conditions. This provides insight into how oxidative stress affects ATP23 function.

• Advanced microscopy techniques:
  Super-resolution microscopy combined with ATP23 antibodies permits visualization of ATP23 distribution within mitochondrial subcompartments, offering spatial context for its interactions with partners like Mia40 .

• Peptide array technologies:
  Peptide arrays like those used in dot blot assays are being expanded to create comprehensive epitope maps for ATP23 antibodies, ensuring more precise targeting of functional domains.

• CRISPR-based approaches:
  CRISPR-Cas9 genome editing allows creation of endogenously tagged ATP23 variants, enabling live-cell imaging and functional studies without overexpression artifacts. These approaches also facilitate domain-specific mutations to separate proteolytic and chaperone functions .

• Protein-fragment complementation assays:
  Split-protein complementation systems fused to ATP23 and potential interaction partners provide real-time monitoring of protein-protein interactions in living cells, particularly valuable for studying dynamic aspects of ATP23 chaperone function.

These technical advances collectively enhance our ability to study ATP23 biology with increased spatial, temporal, and functional resolution.